Jaguar Health, Inc.
10.8.2021 22:31:50 CEST | ACCESS Newswire | Press release
Registration link for webcast appears below
Company plans to file Q2 2021 10-Q on August 13, 2021
SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company investor webcast scheduled for Friday, August 13, 2021 will take place at 8:00 a.m. Eastern Time instead of 8:30 a.m.
Participation Instructions for Webcast
When: Friday, August 13, 2021 at 8:00 AM Eastern Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the Company's expectation that an investor webcast will take place August 13, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/659222/Jaguar-Health-Announces-Time-Change-for-Friday-August-13th-Investor-Webcast-to-800-AM-Eastern-Time
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of ESE World from Amcor30.6.2026 13:50:00 CEST | Press release
PARIS, FR / ACCESS Newswire / June 30, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has completed the acquisition of ESE World (the "Company" or "ESE") from Amcor, one of the world's leading packaging companies. ESE is Europe's leading manufacturer of waste and recycling container systems, serving municipalities and businesses globally. The Company produces mobile waste containers, collection banks, hazardous materials containers, and public furnishing solutions from three manufacturing facilities in Germany (Neuruppin and Olpe) and France (Crissey), generating approximately €300m in revenues. Having completed the carve-out from Amcor, ESE will operate as an independent company with the focus and resources to pursue its next phase of growth. Pacific Avenue will work in close partnership with the management te
Multi-Billion-Dollar Global Sports Brand U.S. Polo Assn. Earns Global Awards and Recognitions Across Business, Sport, and Content Categories30.6.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / June 30, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), continues to gain global momentum in 2026, earning a series of high-profile honors and recognitions that reflect the brand's expanding footprint, deepening consumer trust, and growing influence in sports-driven content and storytelling. Among U.S. Polo Assn.'s top recognitions this year, the global, multi-billion-dollar brand was honored at the 11th Annual 2026 Globee Awards for Achievement with Gold for the "Global Expansion" category and Silver for the "Brand Development" category. These awards highlight U.S. Polo Assn.'s ability to scale its authentic, sport-inspired brand across more than 190 countries while building a consistent and relevant brand in diverse markets worldwide. The recognition follows a record-setting $2.7 billion in global retail sales in 2025, reinforcing the brand's continued upward trajectory. Trust and consumer credi
Tenstorrent Sets New Performance Records, Launches TT- Ascalon S, and Expands Across Japan30.6.2026 08:30:00 CEST | Press release
At TT-Deploy JP, Tenstorrent set new records on language and video models, launched TT-Ascalon S RISC-V CPU IP for agentic AI, and joins ai&'s sovereign heterogenous inference platform with Tenstorrent Galaxy™ superclusters, a general-purpose system that can drop in beside GPUs or stands alone. TOKYO, JP / ACCESS Newswire / June 30, 2026 / Tenstorrent, the AI compute company led by CEO Jim Keller, today at TT-Deploy JP set new performance records across language and video, launched TT-Ascalon S RISC-V CPU IP for agentic AI, and detailed its largest deployment to date, a general-purpose, heterogenous AI build in Japan. Each rests on the same foundation: a single architecture that runs major AI workloads faster than GPUs and scales from a licensable core to a Tenstorrent Galaxy™ supercluster over standard Ethernet. That makes Tenstorrent's Networked AI architecture a different kind of solution - open, general-purpose, flexible for heterogeneous or stand alone deployments, and backed by A
Freedom Holding Corp. Founder Timur Turlov Announces Candidacy for FIDE Deputy President29.6.2026 15:25:00 CEST | Press release
ALMATY, KAZAKHSTAN AND NEW YORK, NY / ACCESS Newswire / June 29, 2026 / Timur Turlov, President of the Kazakhstan Chess Federation and founder and majority shareholder of Freedom Holding Corp., has announced his candidacy for the position of Deputy President of the International Chess Federation (FIDE). According to Turlov, his decision to run reflects the work the Kazakhstan Chess Federation has undertaken in recent years to develop, digitize and popularize chess across the country. "My goal is to bring more stability, balance and mutual understanding to FIDE. Freedom Holding Corp., as one of Central Asia's leading fintech groups, can help the federation become more digital and technology-driven," said Timur Turlov. He added that his candidacy also reflects Kazakhstan's growing role in the international chess community. "In this sense, I represent not only myself, but also Kazakhstan - a country that is increasingly seen internationally as a reliable partner, capable of building calm
Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting27.6.2026 01:40:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 26, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that all six director nominees proposed by management were elected as directors of the Company at its annual meeting of shareholders held via live video webcast today. Each director will hold office until the close of the next annual meeting of the Company's shareholders or until their successors are duly elected or appointed. The following are the voting results based on proxies received and a vote by online ballot: Director Number of Votes Percentage of Votes Votes For: Votes Withheld: Votes For: Votes Withheld: Jaime Guillen 9,351,125 220,821 97.69% 2.31% James V. Lawless 9,345,405 226,541 97.63% 2.37% Marc Murnaghan 9,355,472 216,474 97.74% 2.26% Marcela Paredes de Vásquez 9,383,074 188,872 98.03% 1.97% Catherine Fagnan 9,386,661 185,285 98.06% 1.94% Adarsh P. Mehta 9,394,433 177,513 98.15% 1.85% About Polaris Renewable Energy Inc. Polaris Ren
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom